These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8098665)

  • 1. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
    Lauritzsen GF; Bogen B
    Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z; Hofgaard PO; Omholt H; Bogen B
    Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
    Dembic Z; Schenck K; Bogen B
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
    Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
    Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some cloned murine CD4+ T cells recognize H-2Ld class I MHC determinants directly. Other cloned CD4+ T cells recognize H-2Ld class I MHC determinants in the context of class II MHC molecules.
    McKisic MD; Sant AJ; Fitch FW
    J Immunol; 1991 Nov; 147(9):2868-74. PubMed ID: 1717578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
    Bogen B
    Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoregulation by processed immunoglobulin on B-cells.
    Ghosh SK; Chakrabarti D
    Indian J Biochem Biophys; 1993 Dec; 30(6):414-21. PubMed ID: 7911781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC.
    Grogg D; Hahn S; Erb P
    Eur J Immunol; 1992 Jan; 22(1):267-72. PubMed ID: 1346113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterization of target cell recognition by in vivo or in vitro activated CD4+ killer T cells.
    Erb P; Grogg D; Troxler M; Kennedy M; Fluri M
    J Immunol; 1990 Feb; 144(3):790-5. PubMed ID: 1967273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
    Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
    Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.
    Lauritzsen GF; Weiss S; Dembic Z; Bogen B
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5700-4. PubMed ID: 7911244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.
    Gricks CS; Rawlings E; Foroni L; Madrigal JA; Amlot PL
    Cancer Res; 2001 Jul; 61(13):5145-52. PubMed ID: 11431353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accessory cells in immune suppression. II. Evidence for presentation of idiotype-specific suppressor factors to B cell targets by I-A+ accessory cells.
    Moser G; Kauffman MG; Abbas AK
    J Immunol; 1985 May; 134(5):2867-71. PubMed ID: 2580003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
    Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
    J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isotypic residues in the membrane proximal domain of MHC class II beta-chains control activation of CD4+ T cells.
    Sant AJ
    J Immunol; 1993 Jun; 150(12):5299-310. PubMed ID: 8099935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB; Sandlie I; Bogen B
    Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of idiotype-specific CD4+ T-cell line: cellular processing of exogenous self-immunoglobulin.
    Sakato N; Rugdech P; Yoda T; Ota A; Zhao Y; Semma M; Suzuki Y; Fujio H
    Immunology; 1990 Oct; 71(2):153-7. PubMed ID: 2228018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.